Patents by Inventor Kuei-Ying Lin

Kuei-Ying Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030176677
    Abstract: Compounds having structure (1) 1
    Type: Application
    Filed: November 14, 2002
    Publication date: September 18, 2003
    Inventors: Kuei-Ying Lin, Mark D. Matteucci
  • Patent number: 6617437
    Abstract: Compounds having particular interest as labels and various novel uses in diagnostics and therapeutics are provided which have structure (1) wherein R1 is a binding partner, a linker or H; a and b are 0 or 1, provided that the total of a and b is 0 or 1; A is N or C; X is S, O, —C(O)—, NH or NCH2R6; Y is —C(O)—; Z is taken together with A to form an aryl or heteroaryl ring structure comprising 5 or 6 ring atoms wherein the heteroaryl ring comprises a single O ring heteroatom, a single N ring heteroatom, a single S ring heteroatom, a single O and a single N ring heteroatom separated by a carbon atom, a single S and a single N ring heteroatom separated by a carbon atom, 2 N ring heteroatoms separated by a carbon atom, or 3 N ring heteroatoms at least two of which are separated by a carbon atom, and wherein the aryl or heteroaryl ring carbon atoms are unsubstituted with other than H or at least 1 nonbridging ring carbon atom is substituted with R6 or ═O; R6 is
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: September 9, 2003
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Robert J. Jones, Kuei-Ying Lin
  • Patent number: 6610664
    Abstract: The present invention is directed to new cationic lipids and intermediates in their synthesis that are useful for transfecting nucleic acids or peptides into prokaryotic or eukaryotic cells. The lipids comprise one or two substituted histidine residues, or similar compounds, linked to a lipophilic moiety. The lipids form a complex when mixed with polyanions such as nucleic acids or peptides. The complexes permit efficient transfer of polyanions into cells, usually without significant toxicity to the cells.
    Type: Grant
    Filed: June 4, 2002
    Date of Patent: August 26, 2003
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kuei-Ying Lin, Mark D. Mattuecci
  • Publication number: 20030072712
    Abstract: Compounds having structure (1) 1
    Type: Application
    Filed: May 21, 2002
    Publication date: April 17, 2003
    Inventors: Kuei-Ying Lin, Mark D. Matteucci
  • Publication number: 20030069392
    Abstract: The present invention is directed to new cationic lipids and intermediates in their synthesis that are useful for transfecting nucleic acids or peptides into prokaryotic or eukaryotic cells. The lipids comprise one or two substituted histidine residues, or similar compounds, linked to a lipophilic moiety. The lipids form a complex when mixed with polyanions such as nucleic acids or peptides. The complexes permit efficient transfer of polyanions into cells, usually without significant toxicity to the cells.
    Type: Application
    Filed: June 4, 2002
    Publication date: April 10, 2003
    Inventors: Kuei-Ying Lin, Mark D. Mattuecci
  • Patent number: 6437121
    Abstract: The present invention is directed to new cationic lipids and intermediates in their synthesis that are useful for transfecting nucleic acids or peptides into prokaryotic or eukaryotic cells. The lipids comprise one or two substituted histidine residues, or similar compounds, linked to a lipophilic moiety. The lipids form a complex when mixed with polyanions such as nucleic acids or peptides. The complexes permit efficient transfer of polyanions into cells, usually without significant toxicity to the cells.
    Type: Grant
    Filed: April 25, 2000
    Date of Patent: August 20, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Kuei-Ying Lin, Mark D. Mattuecci
  • Patent number: 6414127
    Abstract: Compounds having structure (1) wherein R1 is —H a protecting group, a linker or a binding partner; and R2 and R34 are as defined in the specification. The invention also provides intermediates and methods make the structure (1) compounds, as well as methods to use the compounds as labels in diagnostic assays and to enhance binding to complementary bases.
    Type: Grant
    Filed: September 21, 1999
    Date of Patent: July 2, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Kuei-Ying Lin, Mark D. Matteucci
  • Publication number: 20010041794
    Abstract: Nucleotide analogs characterized by the presence of an amidate linked amino acid or an ester linked group which is bonded to the phosphorus atom of phosphonate nucleotide analogs are disclosed. The analogs comprise a phosphoamidate or ester bond that is hydrolyzed in vivo to yield a corresponding phosphonate nucleotide analog. Methods and intermediates for their synthesis and use are described.
    Type: Application
    Filed: March 7, 2001
    Publication date: November 15, 2001
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Norbert W. Bischofberger, Robert J. Jones, Murty N. Arimilli, Kuei-Ying Lin, Michael S. Louie, Lawrence R. McGee, Ernest J. Prisbe, William A. Lee, Kenneth C. Cundy
  • Patent number: 6225460
    Abstract: Nucleotide analogs characterized by the presence of an amidate linked amino acid or an ester linked group which is bonded to the phosphorus atom of phosphonate nucleotide analogs are disclosed. The analogs comprise a phosphoamidate or ester bond that is hydrolyzed in vivo to yield a corresponding phosphonate nucleotide analog. Methods and intermediates for their synthesis and use are described.
    Type: Grant
    Filed: February 10, 1999
    Date of Patent: May 1, 2001
    Assignee: Gilead Sciences, Inc.
    Inventors: Norbert W. Bischofberger, Robert J. Jones, Murty N. Arimilli, Kuei-Ying Lin, Michael S. Louie, Lawrence R. McGee, Ernest J. Prisbe, William A. Lee, Kenneth C. Cundy
  • Patent number: 6093816
    Abstract: The present invention is directed to new cationic lipids and intermediates in their synthesis that are useful for transfecting nucleic acids or peptides into prokaryotic or eukaryotic cells. The lipids comprise one or two substituted histidine residues, or similar compounds, linked to a lipophilic moiety. The lipids form a complex when mixed with polyanions such as nucleic acids or peptides. The complexes permit efficient transfer of polyanions into cells, usually without significant toxicity to the cells.
    Type: Grant
    Filed: June 27, 1996
    Date of Patent: July 25, 2000
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kuei-Ying Lin, Mark D. Mattuecci
  • Patent number: 6028183
    Abstract: Compounds having structure (1) ##STR1## wherein R.sup.1 is --H a protecting group, a linker or a binding partner; and R.sup.2 and R.sup.34 are as defined in the specification. The invention also provides intermediates and methods make the structure (1) compounds, as well as methods to use the compounds as labels in diagnostic assays and to enhance binding to complementary bases.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: February 22, 2000
    Assignee: Gilead Sciences, Inc.
    Inventors: Kuei-Ying Lin, Mark D. Matteucci
  • Patent number: 6007992
    Abstract: Compounds having structure (1) ##STR1## wherein R.sup.1 is --H a protecting group, a linker or a binding partner; and R.sup.2 and R.sup.34 are as defined in the specification. The invention also provides intermediates and methods make the structure (1) compounds, as well as methods to use the compounds as labels in diagnostic assays and to enhance binding to complementary bases.
    Type: Grant
    Filed: November 10, 1997
    Date of Patent: December 28, 1999
    Assignee: Gilead Sciences, Inc.
    Inventors: Kuei-Ying Lin, Mark D. Matteucci
  • Patent number: 6005096
    Abstract: A compound having the structure ##STR1## wherein R.sup.1 is H or a linker group; R.sup.24 is independently halo or C.sub.1 -C.sub.2 haloalkyl;R.sup.25 is independently --SH, --OH, .dbd.S or .dbd.O;A is independently N or C; andM, taken together with the radical --A--C(--R.sup.25), completes an aryl or heteroaryl ring structure comprising 5 or 6 ring atoms wherein the heteroaryl ring comprises a single O ring heteroatom, a single N ring heteroatom, a single S ring heteroatom, a single O and a single N ring heteroatom separated by a carbon atom, a single S and a single N ring heteroatom separated by a carbon atom, 2 N ring heteroatoms separated by a carbon atom, or 3 N ring heteroatoms at least two of which are separated by a carbon atom, and wherein the aryl or heteroaryl ring carbon atoms are unsubstituted with other than H or at least 1 nonbridging ring carbon atom is substituted with R.sup.6 ;R.sup.6 is independently H, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, NO.sub.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: December 21, 1999
    Assignee: Gilead Sciences, Inc.
    Inventors: Mark Matteucci, Robert J. Jones, Kuei-Ying Lin
  • Patent number: 5777153
    Abstract: The present invention is directed to new cationic lipids and intermediates in their synthesis that are useful for transfecting nucleic acids or peptides into prokaryotic or eukaryotic cells. The lipids comprise one or two arginine, lysine or ornithine residues linked to a lipophilic moiety. The lipids form a composition when mixed with polyanions such as nucleic acids. The compositions permit efficient transfer of polyanions into cells without significant toxicity to the cells.
    Type: Grant
    Filed: July 8, 1994
    Date of Patent: July 7, 1998
    Assignee: Gilead Sciences, Inc.
    Inventors: Kuei-Ying Lin, Jason G. Lewis, Mark D. Matteucci, Richard W. Wagner
  • Patent number: 5763208
    Abstract: Oligonucleotides that are capable of passive diffusion across cell membranes are disclosed. These oligonucleotides contain at least two nucleotide residues and show a log distribution coefficient in octanol:water of about 0.0-2.5 and a solubility in water of at least 0.001 .mu.g/mL. In preferred embodiments, either at least 80% of the internucleotide linkages are non-ionic, or at least 80% of the bases contain lipophilic hydrocarbyl substitutions, or a combination of these sums to 80%. These oligonucleotides may be conjugated to label and used to visualize cells.
    Type: Grant
    Filed: February 28, 1996
    Date of Patent: June 9, 1998
    Assignee: Gilead Sciences, Inc.
    Inventors: Norbert Bischofberger, Ken Kent, Rick Wagner, Chris Buhr, Kuei-Ying Lin
  • Patent number: 5705693
    Abstract: The present invention is directed to new cationic lipids and intermediates in their synthesis that are useful for transfecting nucleic acids or peptides into prokaryotic or eukaryotic cells. The lipids comprise one or two substituted arginine, lysine or ornithine residues, or derivatives thereof, linked to a lipophilic moiety. The lipids form a complex when mixed with polyanions such as nucleic acids or peptides. The complexes permit efficient transfer of polyanions into cells, usually without significant toxicity to the cells.
    Type: Grant
    Filed: July 7, 1995
    Date of Patent: January 6, 1998
    Assignee: Gilead Sciences, Inc.
    Inventors: Randolph B. DePrince, Kevin L. Facchine, George S. Lewis, Jason G. Lewis, Kuei-Ying Lin, Mark D. Matteucci, Robert A. Mook, Jr., Richard W. Wagner
  • Patent number: 5656745
    Abstract: Nucleotide analogs characterized by the presence of an amidate linked amino acid or an ester linked group which is bonded to the phosphorus atom of phosphonate nucleotide analogs are disclosed. The analogs comprise a phosphoamidate or ester bond that is hydrolyzed in vivo to yield a corresponding phosphonate nucleotide analog. Methods and intermediates for their synthesis and use are described.
    Type: Grant
    Filed: September 17, 1993
    Date of Patent: August 12, 1997
    Assignee: Gilead Sciences, Inc.
    Inventors: Norbert Bischofberger, Robert J. Jones, Murty Arimilli, Kuei-Ying Lin, Michael Louie, Lawrence R. McGee, Ernest J. Prisbe
  • Patent number: 5633360
    Abstract: Oligonucleotides that are capable of passive diffusion across cell membranes are disclosed. These oligonucleotides contain at least two nucleotide residues and show a log distribution coefficient in octanol:water of about 0.0-2.5 and a solubility in water of at least 0.001 .mu.g/mL. In preferred embodiments, either at least 80% of the internucleotide linkages are non-ionic, or at least 80% of the bases contain lipophilic hydrocarbyl substitutions, or a combination of these sums to 80%. These oligonucleotides may be conjugated to label and used to visualize cells.
    Type: Grant
    Filed: April 14, 1992
    Date of Patent: May 27, 1997
    Assignee: Gilead Sciences, Inc.
    Inventors: Norbert Bischofberger, Ken Kent, Rick Wagner, Chris Buhr, Kuei-Ying Lin
  • Patent number: 5502177
    Abstract: A compound having the structure: ##STR1## wherein R.sup.1 is an oligonucleotide;a is 1 and b is 0;A is C or CH;X is S, O, NH or NCH.sub.2 R.sup.6 ;Z is taken together with A to form an aryl ring structure comprising 6 ring atoms wherein the aryl ring carbon atoms are unsubstituted with other than H or at least 1 nonbridging ring carbon atom is substituted with R.sup.6 or .dbd.O;R.sup.6 is independently H, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, NO.sub.2, N(R.sup.3).sub.2, C.tbd.N or halo, or an R.sup.6 is taken together with an adjacent Z group R.sup.6 to complete a phenyl ring; andR.sup.3 is a protecting group or H; and tautomers, solvates and salts thereof.
    Type: Grant
    Filed: September 17, 1993
    Date of Patent: March 26, 1996
    Assignee: Gilead Sciences, Inc.
    Inventors: Mark D. Matteucci, Robert J. Jones, Kuei-Ying Lin
  • Patent number: 5495009
    Abstract: Modified oligomers containing at least one internucleoside linkage of the formula Y.sup.1 CX.sub.2 y.sup.2 wherein at least one of Y.sup.1 and Y.sup.2 is sulfur and the other is oxygen and wherein each X is the same or different and is a stabilizing substituent are disclosed. These oligomers show superior binding properties and are thus useful for binding target substances in analytical uses. Also disclosed are improved methods for synthesis of oligomers containing linkages of the general formula --YCX.sub.2 Y-- wherein each Y may be independently oxygen or sulfur.
    Type: Grant
    Filed: April 24, 1992
    Date of Patent: February 27, 1996
    Assignee: Gilead Sciences, Inc.
    Inventors: Mark Matteucci, Bob Jones, Kuei-Ying Lin